Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818187 | 1.00 | FFAR1 (0.42) | FFAR1KDM4ELMNAGRM2AGTR2 | |
| SCHEMBL1815343 | 0.91 | FFAR1 (0.42) | FFAR1KDM4ELMNAGRM2AGTR2 | |
| SCHEMBL1815689 | 0.91 | FFAR1 (0.42) | FFAR1KDM4ELMNAGRM2AGTR2 | |
| SCHEMBL1819080 | 0.91 | FFAR1 (0.41) | FFAR1KDM4ELMNAGRM2AGTR2 | |
| SCHEMBL1815413 | 0.91 | FFAR1 (0.41) | FFAR1KDM4ELMNAGRM2AGTR2 | |
| SCHEMBL1816467 | 0.90 | FFAR1 (0.41) | FFAR1KDM4ELMNAGRM2AGTR2 | |
| SCHEMBL1816555 | 0.90 | FFAR1 (0.41) | FFAR1KDM4ELMNAGRM2AGTR2 | |
| SCHEMBL1815651 | 0.90 | FFAR1 (0.38) | FFAR1AGTR2 | |
| SCHEMBL1818236 | 0.90 | FFAR1 (0.38) | FFAR1AGTR2 | |
| SCHEMBL1816264 | 0.84 | FFAR1 (0.41) | FFAR1KDM4ELMNAGRM2AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, OPRD1 | FFAR1 330/4885KDM4E 4301/4885LMNA 1437/4885 |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, CHRNG | FFAR1 393/4885KDM4E 4524/4885LMNA 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.